Lunesta Schedule IV Placement Effective Immediately, DEA Says

The Drug Enforcement Administration's final rule designates Lunesta (eszoplicone) as a Schedule IV controlled substance. Sepracor planned to launch the insomnia agent on the day of the ruling.